2610.0000 -16.60 (-0.63%)
NSE Nov 17, 2026 15:31 PM
Volume: 324.6K
 

2610.00
-0.63%
Motilal Oswal
Mankind’s domestic formulation (DF) business is witnessing a healthy revival, with Mar’26 growth at 11.5% YoY vs. IPM growth at 10.6% (1.1pp outperformance).
Mankind Pharma Ltd. is trading above all available SMAs
More from Mankind Pharma Ltd.
Recommended